Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD by 2028. billion USD in 2023 to $166.53 Image thumbnail-qh33.jpg

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

Alta Sciences

APRIL 5, 2024

The mini documentary explores transformation in the slow-to-change drug development industry. Leaders from Altasciences dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and drug sponsors, and how Altasciences has broken from tradition to address these challenges.

Drug Development 52

Drug Development Pharma Companies Marketing Drugs 52

Perficient: Drug Development

SEPTEMBER 25, 2023

And that’s easy to understand due to the plethora of available options and new solutions entering the market each day. According to Forrester, “Investment in hospital equipment will grow from $36 billion in 2018 to $262 billion in 2028. For many HCPs, a significant challenge we often see is technology overwhelm.

Nurses 98

Nurses Hospitals Production Marketing 98

Perficient: Drug Development

SEPTEMBER 19, 2023

jobs by 2028. Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

Licensing 59

Licensing Licensing Production Marketing 59

DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.    The average cost of bringing a new drug to market is about $2.6 trillion by 2028. million deaths in 2022.

Pharmaceuticals 76

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 76

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. The study is planned to begin in 2026 and conclude in 2028.

FDA 40

FDA Trials Therapies Regulations 40

Codon

SEPTEMBER 29, 2024

2028 Over the next year, the scientific community ferociously interrogated the model. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. 2032 Curiously, the reliance on artificial intelligence in biology did not change typical clinical market dynamics.

Engineering 126

Engineering Virus DNA Therapies 126